Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

European Regulatory Committee Recommends Rejecting Puma Biotechnology’s Breast Cancer Medicine

17h biospace
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) offered a negative opinion on Puma Biotechnology’s application for neratinib for breast cancer. (11-0)

Your Daily Pharma Scoop: Clovis Oncology Gets A Boost, Mesoblast Positive Data, Kadmon's Updated Results

2018-02-24 seekingalpha
Today we will discuss Clovis Oncology (CLVS). Clovis Oncology have had a good run this week, gaining more than 11%. The stock though still remains down more than 21% in the last six months and well-off its 52-week high of $99.45. (375-0)

Is a Beat in Store for Horizon Pharma (HZNP) in Q4 Earnings?

2018-02-23 zacks
We expect Horizon Pharma plc (HZNP - Free Report) to beat expectations when it reports fourth-quarter 2017 results on Feb 28, before the opening bell. (44-0)

What's in the Cards for Merrimack (MACK) in Q4 Earnings?

2018-02-23 zacks
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) is expected to report fourth-quarter 2017 results on Mar 7. Last quarter, Merrimack beat bottom-line expectations by 78.72%. (62-0)

Can Rhopressa's Approval Drive Aerie (AERI) in Q4 Earnings?

2018-02-23 zacks
Aerie Pharmaceuticals, Inc. (AERI - Free Report) is expected to report fourth-quarter 2017 results on Feb 28, after market closes. Last quarter, the company reported a wider-than-expected loss. (51-0)

PBYI / Puma Biotechnology Inc. 8-K (Current Report)

2018-02-23 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2018     PUMA BIOTECHNOLOGY, INC. (Exact Name of Registrant as Specified in its Charter)       Delaware   001-35703   77-0683487 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No. (11-0)

EU panel recommends against nod for Puma Biotech's breast cancer drug

2018-02-23 reuters
(Reuters) - A European Medicines Agency (EMA) panel on Friday recommended against approving Puma Biotechnology’s lead breast cancer drug, an outcome the U.S drugmaker had signaled last month. (11-1)

Is a Beat in the Cards for Perrigo (PRGO) in Q4 Earnings?

2018-02-21 zacks
We expect Perrigo Company plc (PRGO - Free Report) to beat estimates when it reports fourth-quarter 2017 and full-year results before the opening bell on Feb 27. (61-0)

Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect?

2018-02-21 zacks
Jazz Pharmaceuticals plc (JAZZ - Free Report) is scheduled to report fourth-quarter results on Feb 27 after market close. (32-0)

What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?

2018-02-20 zacks
Juno Therapeutics Inc. (JUNO - Free Report) is expected to report fourth-quarter 2017 results on Mar 7, after the market closes. Last quarter, the company delivered a positive earnings surprise of 10.98%. (106-0)

What to Expect From BioMarin (BMRN) This Earnings Season?

2018-02-20 zacks
BioMarin Pharmaceutical Inc. (BMRN - Free Report) will report fourth-quarter and full-year 2017 results on Feb 22, after market close. BioMarin delivered a positive earnings surprise of 41.67% in the last quarter. (78-0)

What's in Store for Ligand (LGND) This Earnings Season?

2018-02-19 zacks
Ligand Pharmaceuticals Incorporated (LGND - Free Report) is scheduled to report fourth-quarter 2017 results on Feb 21, after the market closes. Ligand’s earnings history has been a mixed bag with the company surpassing expectations in two of the last four quarters and missing in the other two. It also delivered an average beat of 8.22%. (76-0)

PBYI / Puma Biotechnology Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) PUMA BIOTECHNOLOGY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 74587V107 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

PBYI / Puma Biotechnology Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) PUMA BIOTECHNOLOGY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 74587V107 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

PBYI / Puma Biotechnology Inc. / ORBIMED ADVISORS LLC - 13G/A (Passive Investment)

2018-02-13 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 2)*   Puma Biotechnology, Inc. (Name of Issuer)     Common Stock (Title of Class of Securities)     74587V107 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b) o Rule 13d-1(c) o Rule 13d-1(d)     *


CUSIP: 74587V107